Introduction
============

Type 2 diabetes mellitus is a syndrome of disordered metabolism with inappropriate hyperglycemia due to both an absolute deficiency of insulin secretion and a reduction in the biological effectiveness of insulin. The chronic exposure to high levels of blood glucose is an important factor leading to diabetic vascular complications. Diabetes mellitus is an independent risk factor for cardiovascular disease, cerebrovascular disease, and peripheral vascular disease. According to the Multiple Risk Factor Interventional Trial (MRFIT), patients with diabetes mellitus are known to be affected by cardiovascular disease three times as frequently as nondiabetic subjects, with adjustment for other risk factors ([@b48]). From the two mega trial studies with type 1 diabetes mellitus and type 2 diabetes mellitus, establishing that the intensive glycemic control decreases the incidence of macrovascular complications has proved much more elusive than the established beneficial effects on microvascular complications such as retinopathy or renal disease ([@b15]; [@b51]). Diabetic macrovascular complications occur by complex mechanisms consisting of atherosclerosis, thrombosis, and hemodynamic abnormalities. Among them, atherosclerosis is an important component for diabetic macrovascular complications. Thus, understanding the pathophysiology of atherosclerosis in diabetes mellitus and prevention of atherosclerotic vascular diseases are clinically important issues. Vascular endothelial dysfunction is an early event of diabetic macroangiopathies ([@b49]). A number of pharmacotherapeutic approaches for correcting impaired endothelial function, such as antioxidants, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, tetrahydrobiopterin, methytetrahydrofolic acid, and arginine, have been investigated (for a comprehensive review, see [@b59]). In this review, we focus on two kinds of reagents targeting vascular endothelium for the prevention and treatment of atherosclerosis in patients with type 2 diabetes mellitus: the prostaglandin (PG) I~2~ analog beraprost sodium, and the peroxisome proliferators-activated receptor (PPAR)α activator fenofibrate.

Hyperglycemia as a target of antiatherosclerotic therapy in type 2 diabetes mellitus
====================================================================================

Macrovascular complications of diabetes mellitus are postulated as distinct from diabetic microvascular complications due to their pathophysiology and epidemiology. It has been shown that a 1% increase in glycosylated hemoglobin (HbA1c) resulted in a 70% increase in proliferative retinopathy, but only a 10% increase in cardiovascular events ([@b33]). Thus, hyperglycemia is a dominant risk factor for diabetic retinopathy or diabetic kidney disease, but it showed not to be the only risk factor for atherosclerosis in diabetic patients.

In our analysis of 125 type 2 diabetic patients without microvascular complications, 50% of the patients were diagnosed as having atherosclerosis of the carotid arteries based on ultrasonographic evaluation. Risk factors for early atherosclerosis of the carotid arteries were age, low-density lipoprotein (LDL)-cholesterol, hypertension, and diabetes treatment, but neither fasting plasma glucose, HbA1c, nor known diabetes duration ([@b23]). These results indicate that glycemic control estimated by fasting plasma glucose and HbA1c levels is poorly related to asymptomatic atherosclerosis in type 2 diabetic patients without diabetic microvascular complications.

Recent epidemiological studies suggest that postprandial hyperglycemia may be a risk factor of cardiovascular disease beyond and more powerful than fasting hyperglycemia ([@b3]). A possible mechanism is that hyperglycemia after meals causes an overproduction of free radicals and thrombin proportional to blood glucose levels in type 2 diabetic patients ([@b9]). Moreover, acute elevation of glucose levels in healthy subjects reduces nitric oxide (NO) availability ([@b22]) and increases the circulating levels of some cellular adhesion molecules ([@b34]). In subjects with normal glucose tolerance (NGT) and those with impaired glucose tolerance (IGT), acute hyperglycemia increases circulating cytokine concentrations by an oxidative mechanism ([@b18]). Oral glucose tolerance test (OGTT)-2 h glucose is an important predictor for plasma high-sensitivity C-reactive protein level, an associated marker of cardiovascular disease, in nondiabetic subjects ([@b28]). It has been reported that reduction of postprandial hyperglycemia in type 2 diabetic patients is associated with carotid atherosclerosis regression ([@b17]) and cardiovascular events ([@b26]).

Hypertension and dyslipidemia as targets of antiatherosclerotic therapy in type 2 diabetes mellitus
===================================================================================================

To prevent cardiovascular events in patients with type 2 diabetes mellitus, therapeutic strategies that have been shown by clinical trials include antihypertensive therapy, lipid-lowering therapy, and antiplatelet therapy.

The tight control of blood pressure has been shown to reduce the incidence of deaths related to diabetes, stroke, diabetic microvascular endpoints, progression of diabetic retinopathy, and deterioration in visual acuity ([@b52]). However, there was no significant reduction in all cause mortality and myocardial infarction in that study, but the study was not powered to detect moderate changes in these parameters. By contrast, subanalysis of the Hypertension Optimal Treatment (HOT) study showed that intensive lowering of diastolic blood pressure was associated with significant reductions in cardiovascular events in diabetic patients, although it failed to demonstrate the beneficial effects of tight blood pressure control on the prevention of myocardial infarction and stroke ([@b27]).

There is a substantial group of type 2 diabetes patients in whom the levels of both plasma triglyceride and LDL-cholesterol are elevated and with low high-density lipoprotein (HDL) cholesterol. Treatment with the statin class of lipid-lowering drugs (HMG-CoA reductase inhibitors) efficiently corrects the elevated LDL-cholesterol level. In the Anglo-Scandinavian Cardiac Outcomes Trail-Lipid Lowering Arm (ASCOT-LLA), atorvastatin could not reduce the risk of nonfatal myocardial infarction and coronary artery heart disease death in patients with diabetes and hypertension who had no preexisting coronary heart disease, although LDL-cholesterol level in the atorvastatin group was 1.2 mmol/L lower than the placebo group ([@b44]). The Heart Protection Study (HPS), which included 5963 patients with diabetes who were prospectively randomized to treatment with simvastatin or placebo, demonstrated 27% decrease (p = 0.0007) in major coronary events with active treatment ([@b11]). In the Collaborative Atorvastatin Diabetes Study (CARDS) ([@b10]), 2838 patients with type 2 diabetes mellitus were studied. A significant 37% reduction in cardiovascular events was shown in the atorvastatin group. Overall, some but not all studies have reported significant reduction in coronary heart disease risk with statin therapy in diabetic patients ([@b20]). Statin therapy is shown to have the ability to improve insulin resistance in dyslipidemic type 2 diabetic patients ([@b41]) and endothelial function through increasing the bioavailability of NO ([@b57]). Improvement of flow-mediated dilatation (FMD) after atorvastatin treatment for 6 months has been demonstrated in type 2 diabetic patients ([@b50]), although there have been reports of controversial results with the use of atorvastatin or simvastatin ([@b45]; [@b54]). Thus, the beneficial effect of statins on cardiovascular diseases may be at least in part mediated by improving vascular function, in addition to the effect of controlling dyslipidemia.

The fibric acid derivative fenofibrate significantly reduced the angiographic progression of coronary artery disease in type 2 diabetes mellitus ([@b14]). The favorable effect of fenofibrate on coronary artery disease is indicated to be exerted by increasing the expression of ApoA-I and ApoA-II as well as by increasing LDL particle size ([@b53]). Additionally, since fenofibrate has the ability to activate PPARα more specifically than other fibrates such as gemfibrozil and bezafibrate ([@b32]), the effects of fenofibrate also may be mediated through pleiotropic effects improving endothelial function, which will be shown later.

Multifactorial intervention that targeted hyperglycemia, hypertension, dyslipidemia, and microalubuminuria, along with secondary prevention of cardiovascular disease with aspirin, in patients with type 2 diabetes and microalubuminuria, has been recently shown to reduce the risk of cardiovascular and microvascular events by about 50% ([@b19]).

Adhesion molecules expressed in endothelium as targets of antiatherosclerotic therapy in type 2 diabetes mellitus
=================================================================================================================

Atherosclerosis is characterized by endothelial cell injury, which in turn leads to mononuclear cell adhesion to the endothelium, the initial migration and proliferation of smooth muscle cells, and extracellular matrix deposition ([@b43]). Various adhesion molecules, such as vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), E-selectin, and platelet endothelial cell adhesion molecule (PECAM) have been shown to be highly expressed in atherosclerotic lesions, which might be involved in mononuclear cell adhesion to the vascular endothelium ([@b13]; [@b37]; [@b2]). It has been shown that circulating VCAM-1 level is correlated with early atherosclerosis in patients with type 2 diabetes mellitus ([Figure 1](#fig1){ref-type="fig"}) ([@b38]). The Hoorn study demonstrated that elevated circulating VCAM-1 level is independently associated with an increased future risk of cardiovascular mortality in type 2 diabetes mellitus ([@b29]). Thus, to inhibit the VCAM-1 expression on the vascular endothelium may be a strategy for preventing occurrence and progression of atherosclerosis in patients with type 2 diabetes.

![Relationship between serum circulating vascular cell adhesion molecule (VCAM)-1 and mean intima-medial thickness (mIMT) of carotid arteries in 101 patients with type 2 diabetic mellitus.](vhrm0103-209-f1){#fig1}

VCAM-1 expression is enhanced by various inflammatory molecules such as tumor necrosis factor (TNF)-α and interleukin (IL)-1. The expression of VCAM-1 is known to be inhibited by various reagents such as glucocorticoids ([@b47]), estrogen ([@b5]; [@b46]), progestins ([@b39]), retinoic acid ([@b21]), and fibric acid derivatives ([@b35]; [@b60]).

We recently found that beraprost sodium, orally active PG I~2~ analog, also efficiently inhibited TNF-α-induced VCAM-1 expression in human vascular endothelial cells ([Figure 2a](#fig2){ref-type="fig"}) ([@b23]). Beraprost also decreased the number of human monocytoid cells adhesion to vascular endothelial cells ([Figure 2b](#fig2){ref-type="fig"}). In our clinical study on 25 type 2 diabetic patients who had atherosclerotic change of carotid arteries, the 3-year changes of circulating VCAM-1 level were significantly lower in patients receiving beraprost sodium than those not receiving it ([Figure 3](#fig3){ref-type="fig"}). The 3-year changes of common carotid artery (CCA) intima-medial thickness (IMT) were also significantly lower in those with the beraprost treatment. Studies of 10 patients who could be followed up for 8 years with beraprost treatment showed that their CCA IMT was not significantly changed from 1.17 ± 0.24 mm (SE) to 1.13 ± 0.19 mm after 8 years ([Figure 4](#fig4){ref-type="fig"}). During this course, body mass index, fasting glucose, HbA1c and total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglycerides were not significantly changed in these patients. Based upon the data of the Insulin Resistance Atherosclerosis Study ([@b55]), the average CCA IMT progression reported 0.0072 mm per year in persons with diagnosed diabetes, corresponding to the increases of 0.056 mm in 8 years. Although these data cannot be simply compared with our results shown in [Figure 4](#fig4){ref-type="fig"}, beraprost may be effective long-term for the inhibition of atherosclerosis progression in type 2 diabetes. The sum total of these observations provides the potential of beraprost sodium as an antiatherosclerotic drug in type 2 diabetic patients, at least partly through inhibiting VCAM-1 expression in vascular endothelium.

![(a) Effect of beraprost on cell surface VCAM-1 level in vascular endothelial cells. Vascular endothelial cells were treated for 15 minutes with or without the indicated concentrations of beraprost, and then the cells were stimulated with (hatched bars) or without (open bars) 0.1 ng/mL TNF-α for 2 hours. Cell surface VCAM-1 was determined by whole cell ELISA. Data are means ± SE. \*p \< 0.001 vs TNF-α only, by ANOVA.\
(b) Effects of beraprost on U937 cell adhesion to TNF-α-stimulated vascular endothelial cells. Vascular endothelial cells were treated for 15 minutes with or without 10^−5^ mol/L beraprost and then stimulated with or without 0.1 ng/mL TNF-α for 2 hours. Data are means ± SE. **Abbreviations:** ANOVA, analysis of variance; ELISA, enzyme-linked immunoabsorbent assay; OD, optical density; TNF, tumor necrosis factor; VCAM, vascular cell adhesion molecule.](vhrm0103-209-f2){#fig2}

![Changes in circulating vascular cell adhesion molecule (VCAM-1) level (a) and mean intima-medial thickness (mIMT) of common carotid arteries (b) in 25 patients with type 2 diabetes mellitus receiving (n = 11) or not receiving (n = 14) beraprost for 3 years. Data are means ± SE.](vhrm0103-209-f3){#fig3}

![Changes in mean intima-medial thickness (mIMT) of common carotid arteries in 10 patients with type 2 diabetes mellitus treated with beraprost for 8 years. Data are means ± SE. p = 0.44, by ANOVA (analysis of variance).](vhrm0103-209-f4){#fig4}

It has been shown that PPARα activators fenofibrate and WY14643 inhibited cytokine-induced VCAM-1 expression, resulting in inhibition of leukocyte adherence on vascular endothelial cells ([@b35]). These observations indicate implications regarding the clinical use of the fibrate class of lipid-lowering agents. Although one clinical study of 11 patients with type 2 diabetes showed no significant change in plasma VCAM-1 concentrations by fenofibrate treatment for 6 weeks ([@b16]), a larger cohort study should be investigated.

Endothelial nitric oxide synthase (eNOS) expressed in endothelium as a target for antiatherosclerotic therapy in type 2 diabetes mellitus
=========================================================================================================================================

Endothelium-derived NO is a potent mediator with antiatherogenic properties such as stimulation of vasorelaxation and repression of endothelial leukocyte adhesion molecules, platelet aggregation, and smooth muscle cell proliferation. Endothelial dysfunction due to impaired production and/or action of NO occurs in the early stages of atherosclerosis caused by various risk factors such as hypercholesterolemia ([@b12]), hypertension ([@b40]), cigarette smoking ([@b6]), aging ([@b7]), male sex ([@b7]), and hyperhomocystinemia ([@b58]). Impairment of NO production and its action has also been demonstrated in patients with diabetes mellitus ([@b31]; [@b56]; [@b1]). NO is produced from L-arginine by eNOS. Endothelium-derived NO is responsible for FMD ([@b30]). The FMD of the brachial artery, a parameter of endothelium-dependent vasodilatation, is significantly lower in patients with type 2 diabetes than normal control subjects ([@b56]; [@b36]). Thus, to increase eNOS expression in endothelium may be a potential antiatherogenic target in diabetic patients.

Recent clinical studies have shown that the fibric acid derivative fenofibrate improved vasodilator function. [@b42] showed that fenofibrate significantly improved brachial artery FMD, but not nitroglycerin-mediated dilatation in patients with type 2 diabetes. Fenofibrate significantly increased forearm blood flow in response to acetylcholine, nitroprusside, or verapamil in patients with hypertriglyceridemia ([@b4]). These results indicate that fenofibrate can improve both endothelium-dependent and endothelium-independent vasodilatation. We have shown that fenofibrate and WY14643, also able to activate PPARα, up-regulated eNOS expression in vascular endothelial cells ([@b25]). Bezafibrate, a fibrate drug that potentially activates three types of PPAR (PPARα, -γ, -δ), also increased eNOS expression, whereas rosiglitazone, a specific ligand for PPARγ, failed to increase eNOS expression. Taken together with our result that RU486, shown to have a potential to antagonize PPARα, inhibited the fenofibrate-induced up-regulation of eNOS expression, the fenofibrate-induced up-regulation of eNOS expression was mediated through PPARα. Analysis of the human eNOS promoter sequence (−1600 to +22 nucleotides) did not contain any discernible PPAR response element, and transient transfection of the eNOS promoter construct showed that fenofibrate failed to increase its promoter activity. In addition, the experiments using the transcriptional inhibitor actinomycin D showed that fenofibrate stabilized eNOS mRNA ([Figure 5](#fig5){ref-type="fig"}). These data also suggest direct effects of the fibrates on vessel wall for cardiovascular protection besides lipid-lowering effects. We will see in the near future the results of a large trial that is currently examining the effect of fenofibrate on cardiovascular mortality in patients with type 2 diabetes mellitus (Fenofibrate Intervention and Event Lowering in Diabetes \[FIELD\] study).

![Effects of fenofibrate on endothelial nitric oxide synthase (eNOS) activity and its protein levels in vascular endothelial cells. Vascular endothelial cells were treated for 48 hours with the indicated concentrations of fenofibrate. Data are means ± SE. \*p \< 0.005, \*\*p \< 0.0001 vs control, by ANOVA (analysis of variance).](vhrm0103-209-f5){#fig5}

Conclusion
==========

Atherosclerosis in type 2 diabetes mellitus has been hard to overcome. Multifactorial therapies targeting hyperglycemia, blood pressure, and lipids have proven efficient for reducing cardiovascular events. However, it still remains unclear whether such combination therapy is the best of antiatherosclerotic therapies for type 2 diabetes mellitus, in terms of safety or cost-effectiveness. Here, we demonstrated the potentials of the PGI~2~ analog beraprost and the PPARα activator fenofibrate to target VCAM-1 and eNOS, respectively, in vascular endothelium. These drugs may be added to the lists of antiatherosclerotic modalities for type 2 diabetes.
